BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37553597)

  • 1. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
    Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
    BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
    Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
    Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
    Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
    Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
    J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.